Goldman Sachs’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-322,060
| Closed | -$3.09M | – | 6526 |
|
|
2024
Q4 | $3.09M | Sell |
322,060
-285,298
| -47% | -$1.49M | ﹤0.01% | 3927 |
|
|
2024
Q3 | $1.74M | Buy |
607,358
+105,498
| +21% | +$327K | ﹤0.01% | 4269 |
|
|
2024
Q2 | $1.47M | Buy |
501,860
+51,343
| +11% | +$140K | ﹤0.01% | 4169 |
|
|
2024
Q1 | $1.44M | Sell |
450,517
-20,455
| -4% | -$68.2K | ﹤0.01% | 4096 |
|
|
2023
Q4 | $1.58M | Buy |
470,972
+3,871
| +0.8% | +$9.97K | ﹤0.01% | 4097 |
|
|
2023
Q3 | $1.11M | Buy |
467,101
+217,509
| +87% | +$456K | ﹤0.01% | 4196 |
|
|
2023
Q2 | $439K | Sell |
249,592
-43,770
| -15% | -$112K | ﹤0.01% | 4809 |
|
|
2023
Q1 | $904K | Buy |
293,362
+164,649
| +128% | +$987K | ﹤0.01% | 4447 |
|
|
2022
Q4 | $682K | Buy |
128,713
+54,569
| +74% | +$249K | ﹤0.01% | 4670 |
|
|
2022
Q3 | $262K | Buy |
74,144
+29,429
| +66% | +$97.3K | ﹤0.01% | 5361 |
|
|
2022
Q2 | $116K | Sell |
44,715
-11,762
| -21% | -$32.7K | ﹤0.01% | 5817 |
|
|
2022
Q1 | $253K | Sell |
56,477
-21,455
| -28% | -$96.7K | ﹤0.01% | 5752 |
|
|
2021
Q4 | $531K | Buy |
77,932
+20,757
| +36% | +$141K | ﹤0.01% | 5334 |
|
|
2021
Q3 | $416K | Buy |
57,175
+22,718
| +66% | +$195K | ﹤0.01% | 5310 |
|
|
2021
Q2 | $345K | Sell |
34,457
-4,792
| -12% | -$42.9K | ﹤0.01% | 5437 |
|
|
2021
Q1 | $375K | Sell |
39,249
-2,776
| -7% | -$27.2K | ﹤0.01% | 5307 |
|
|
2020
Q4 | $461K | Buy |
42,025
+5,753
| +16% | +$60.7K | ﹤0.01% | 4656 |
|
|
2020
Q3 | $322K | Buy |
+36,272
| New | +$413K | ﹤0.01% | 4701 |
|
Other funds holding PSTX
Goldman Sachs's PSTX Position: Q1 2025 in Review
Goldman Sachs sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 322,060 shares — an estimated $3.09M sold.
Goldman Sachs first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $3.09M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Goldman Sachs reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Goldman Sachs sold 322,060 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.09M.
- Goldman Sachs first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Goldman Sachs's Poseida Therapeutics, Inc. Common Stock position peaked at $3.09M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.